Investor Relations
Latest Ad-Hoc Releases
- 2011/12/15
- SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
- 2011/08/10
- SYGNIS Pharma AG successfully completes capital increase
- 2011/07/20
- SYGNIS Pharma AG decides on increase in share capital
- 2011/06/15
- SYGNIS Pharma AG secures further financial resources with shareholder loan
- 2010/10/29
- SYGNIS Pharma AG announces strategic restructuring
- 2010/10/28
- Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG
- 2009/10/19
- SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville
- 2008/11/14
- SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG
- 2008/10/15
- SYGNIS Pharma AG Approves Capital Increase
- 2008/06/08
- SYGNIS announces agreement on acquisition of Amnestix Inc.
- 2007/07/22
- SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)
Latest Press Releases
-
Dec 15, 2011
:
SYGNIS Announces Key Results of its Phase II Trial of AX200 in Acute Ischemic Stroke
-
Nov 25, 2011
:
Shareholders support management proposals at SYGNIS Pharma’s AGM with overwhelming majority